Marker Therapeutics Statistics Share Statistics Marker Therapeutics has 11.31M
shares outstanding. The number of shares has increased by 26.81%
in one year.
Shares Outstanding 11.31M Shares Change (YoY) 26.81% Shares Change (QoQ) 5.66% Owned by Institutions (%) 36.68% Shares Floating 7.9M Failed to Deliver (FTD) Shares 2,685 FTD / Avg. Volume 0.22%
Short Selling Information The latest short interest is 103.08K, so 0.96% of the outstanding
shares have been sold short.
Short Interest 103.08K Short % of Shares Out 0.96% Short % of Float 1.25% Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -2.6 and the forward
PE ratio is -0.67.
Marker Therapeutics's PEG ratio is
0.07.
PE Ratio -2.6 Forward PE -0.67 PS Ratio 4.24 Forward PS 4.6 PB Ratio 0 P/FCF Ratio -2.56 PEG Ratio 0.07
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Marker Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 6.36,
with a Debt / Equity ratio of 0.
Current Ratio 6.36 Quick Ratio 6.36 Debt / Equity 0 Debt / EBITDA n/a Debt / FCF n/a Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $1.32M Profits Per Employee $-2.15M Employee Count 5 Asset Turnover 0.3 Inventory Turnover n/a
Taxes Income Tax 49.95K Effective Tax Rate -0.47%
Stock Price Statistics The stock price has increased by -68.85% in the
last 52 weeks. The beta is 1.45, so Marker Therapeutics's
price volatility has been higher than the market average.
Beta 1.45 52-Week Price Change -68.85% 50-Day Moving Average 1.53 200-Day Moving Average 2.09 Relative Strength Index (RSI) 35.51 Average Volume (20 Days) 1,218,912
Income Statement In the last 12 months, Marker Therapeutics had revenue of 6.59M
and earned -10.73M
in profits. Earnings per share was -1.19.
Revenue 6.59M Gross Profit -6.88M Operating Income -11.12M Net Income -10.73M EBITDA -4.53M EBIT -4.53M Earnings Per Share (EPS) -1.19
Full Income Statement Balance Sheet The company has 19.19M in cash and 0 in
debt, giving a net cash position of 19.19M.
Cash & Cash Equivalents 19.19M Total Debt n/a Net Cash n/a Retained Earnings -447.02M Total Assets 16.99M Working Capital 14.49M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -10.91M
and capital expenditures 0, giving a free cash flow of -10.91M.
Operating Cash Flow -10.91M Capital Expenditures n/a Free Cash Flow -10.91M FCF Per Share -1.21
Full Cash Flow Statement Margins Gross margin is -104.34%, with operating and profit margins of -168.68% and -162.81%.
Gross Margin -104.34% Operating Margin -168.68% Pretax Margin -162.05% Profit Margin -162.81% EBITDA Margin -68.68% EBIT Margin -168.68% FCF Margin -165.53%
Dividends & Yields MRKR does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for MRKR is $12.5,
which is 950.4% higher than the current price. The consensus rating is "Strong Buy".
Price Target $12.5 Price Target Difference 950.4% Analyst Consensus Strong Buy Analyst Count 3
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Jan 27, 2023. It was a
backward
split with a ratio of 1:10.
Last Split Date Jan 27, 2023 Split Type backward Split Ratio 1:10
Scores Altman Z-Score -34.66 Piotroski F-Score 4
